Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Sophie Golding"'
Autor:
Manuela Eicher, Sanna Iivanainen, Maria Reig, Amparo Yovanna Castro Sanchez, Anne-Marie Baird, Bogdana Balas, Alberto Bustillos, Sophie Golding, Mathis Mueller-Ohldach, Manfred Welslau, Johannes Ammann
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Introduction Digital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real-world clinical utility/impact. ORIGAMA (
Externí odkaz:
https://doaj.org/article/d84f45f54c0149dcaaf9cd6c718b2e56
Autor:
Sanna Iivanainen, Anne-Marie Baird, Bogdana Balas, Alberto Bustillos, Amparo Yovanna Castro Sanchez, Manuela Eicher, Sophie Golding, Mathis Mueller-Ohldach, Maria Reig, Manfred Welslau, Johannes Ammann
Publikováno v:
BMJ Open. 13:e063242
IntroductionDigital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real-world clinical utility/impact. ORIGAMA (M
Autor:
Sophie Golding, Holger Moch, Christoph B. Westphalen, Ethan Sokol, Andreas Beringer, Ferran Losa, E. Hoglander, Chantal Pauli, N. Chalabi, Alwin Krämer, G. Duran-Pacheco, Jeffrey S. Ross, Linda Mileshkin, A. Karapetyan, Natalie Cook, Tilmann Bochtler, Richard W. Tothill
Publikováno v:
Annals of Oncology. 32:S1227-S1228
Publikováno v:
Ecological Engineering. 120:622-630
The expansion of built infrastructure in the marine environment threatens natural ecological communities at local and regional scales. An increasing interest in incorporating heterogeneity that is reflective of natural rocky shores into artificial st
Autor:
Sophie Golding
Discover the art of being present. Filled with simple advice and inspiring quotes, this book will show you how to appreciate each moment, helping you to live more every day. To experience happiness and fulfilment day to day, you don't need to change
Autor:
Sophie Golding
There are eight billion people on the planet, but there's only one you You're already pretty great. But what if you could feel like the best possible version of yourself every single day? This inspiring little book is full of big ideas to empower you
Autor:
Sophie Golding
Unleash your inner awesomeness! Whether you're stuck in a rut and need some fresh inspiration, or you're looking for guidance on finding happiness, courage or motivation, this book is packed with tips to help you grab life with both hands and make it
Autor:
Sai-Hong Ignatius Ou, Hervé Lena, Anne-Marie C. Dingemans, Shirish M. Gadgeel, Ahmed Kotb, Leena Gandhi, Alice T. Shaw, Dong Wan Kim, Walter Bordogna, Lucio Crinò, Pascal Do, Fabrice Barlesi, James Chih-Hsin Yang, Ali Zeaiter, Sophie Golding, D. Ross Camidge, Javier de Castro, Brett G.M. Hughes
Publikováno v:
European Journal of Cancer, 82, 27-33. ELSEVIER SCI LTD
Background: Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinaseepositive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metasta
Autor:
Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with
Autor:
Alice T. Shaw, Sai-Hong Ignatius Ou, Alberto Chiappori, Tommaso De Pas, Walter Bordogna, Dong Wan Kim, Denis Moro-Sibilot, Ji Youn Han, Antje Tessmer, Shirish M. Gadgeel, Sophie Golding, Ali Zeaiter, D. Ross Camidge, Mark A. Socinski, Eric Dansin, Luigi De Petris, Leena Gandhi, Michael Duruisseaux, Lucio Crinò, Ramaswamy Govindan, James Chih-Hsin Yang
Publikováno v:
Journal of Clinical Oncology. 34:4079-4085
Purpose Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT01871805 an